Tirzepatide Price Breakdown: Name Brand vs. Compounded Options

Understanding the Cost of Tirzepatide Treatment

Tirzepatide has emerged as one of the most effective medications for weight management and type 2 diabetes, but its cost places it out of reach for many patients without insurance coverage. The tirzepatide price varies significantly depending on whether you are prescribed the brand-name product or a compounded alternative from a specialty pharmacy. Understanding these differences can help patients and prescribers make informed decisions about long-term treatment affordability.

Brand-Name Tirzepatide: Mounjaro and Zepbound

Tirzepatide is marketed under two brand names by Eli Lilly. Mounjaro is approved for type 2 diabetes management, while Zepbound carries FDA approval specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Both products contain the same active molecule but are priced and positioned for different indications.

The list price for both Mounjaro and Zepbound runs approximately $1,060 to $1,100 per month for a four-week supply, regardless of dose. Because tirzepatide is titrated from 2.5 mg up to a maximum of 15 mg weekly, the monthly cost remains relatively flat across the dosing schedule. Patients with commercial insurance who qualify for Lilly's savings programs can reduce their out-of-pocket cost to as low as $25 per month, but this assistance is not available to Medicare or Medicaid enrollees. Without any coverage, the annual brand-name cost can exceed $13,000.

Insurance Coverage Realities

Coverage for Mounjaro in the diabetes indication is more common than for Zepbound in the obesity indication. Many employer-sponsored plans and commercial insurers still exclude GLP-1 and GIP/GLP-1 agonists for weight loss, citing budget concerns. Even when covered, prior authorization requirements, step therapy protocols, and high-tier copays remain significant barriers. Medicare Part D plans are prohibited from covering weight-loss drugs, though this may change under pending federal legislation.

Compounded Tirzepatide: What It Is and What It Costs

During periods when brand-name tirzepatide appeared on the FDA drug shortage list, compounding pharmacies were legally permitted to prepare copies of the medication. Compounded tirzepatide — typically supplied as the base peptide in a multi-dose vial — became widely available through telehealth platforms and independent compounding pharmacies. Pricing for compounded versions is substantially lower than brand-name products, generally ranging from $150 to $450 per month depending on dose, the pharmacy, and whether the formulation uses the free base peptide or a salt form such as tirzepatide acetate or tirzepatide hydrochloride.

The lower tirzepatide price from compounders reflects several factors: no branded packaging, no patented drug-device combination pen, bulk peptide sourcing, and no manufacturer markup. Many telehealth programs bundle the prescription, provider visit, and medication shipment into a monthly membership, which can make the total cost more predictable.

Regulatory Status of Compounded Tirzepatide

The FDA removed tirzepatide from its drug shortage list in early 2025, which triggered a phase-out period for compounded versions. Under federal law, compounding of a commercially available drug that is not on the shortage list is generally not permitted for copies of brand-name products. The FDA issued guidance requiring 503A and 503B pharmacies to wind down compounded tirzepatide, though legal challenges from compounding industry groups have created ongoing uncertainty. Patients currently receiving compounded tirzepatide should consult their prescriber about transitioning plans and monitor regulatory updates closely.

Side-by-Side Cost Comparison

• Mounjaro or Zepbound without insurance: approximately $1,060 to $1,100 per month
• Mounjaro or Zepbound with Lilly savings card (eligible commercial patients): as low as $25 per month
• Compounded tirzepatide from a 503A or 503B pharmacy: approximately $150 to $450 per month depending on dose
• Telehealth platforms bundling compounded tirzepatide with care: approximately $200 to $500 per month all-in
• Medicare Part D enrollees: brand-name tirzepatide not covered for weight management; no manufacturer savings card access

How to Reduce Your Out-of-Pocket Costs

For patients pursuing brand-name therapy, the most impactful step is verifying insurance coverage before the first fill. If your plan excludes tirzepatide for weight management, ask your prescriber whether the diabetes indication is clinically appropriate and documentable. Appeal denials with supporting clinical data, as payers sometimes overturn rejections when thorough prior authorization documentation is submitted. Lilly's patient assistance program, Lilly Cares, provides free medication to qualifying uninsured or underinsured patients with incomes below a defined threshold.

Choosing between brand and compounded options ultimately depends on regulatory access, clinical preferences, and budget. As compounding availability narrows following the shortage list removal, the brand-name tirzepatide price will again become the dominant variable for most patients. Planning ahead, exploring insurance appeals, and working with a prescriber who understands formulary navigation are the most reliable strategies for making long-term treatment sustainable.